Evidence map›Paper›PMID 24573997›Full record

ReviewCNS drugs2014

Pharmacological approaches to reducing craving in patients with alcohol use disorders.

Carolina L Haass-Koffler, Lorenzo Leggio, George A Kenna

Abstract readReview
In one paragraph

Review in CNS drugs, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

45 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Yohimbine as a pharmacological probe for alcohol research: a systematic review of rodent and human studies.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2022
    Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Carolina L Haass-KofflerCenter for Alcohol and Addiction Studies, Brown University, Box G-S121-5, Providence, RI, 02812, USA.
Lorenzo Leggio
George A Kenna

Funding

Clinical Psychoneuroendocrinology and Neuropsychopharmacology (CPN)ZIAAA000218 · NIAAA · NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM · PI LEGGIO, LORENZO · 2013 to 2020
$22.8M
ALCOHOL INTERVENTION/TREATMENT OUTCOME RESEARCH TRAININGT32AA007459 · NIAAA · BROWN UNIVERSITY · PI ROBERT MIRANDA, PETER M. MONTI · 1986 to 2026
$13.3M
Aripiprazole and Topiramate on Free-Choice Alcohol UseR01AA015753 · NIAAA · BROWN UNIVERSITY · PI SWIFT, ROBERT M · 2007 to 2011
$2.5M
Matching 5-HT Genotypes to Serotonergic Medications for AlcoholismR01AA016079 · NIAAA · BROWN UNIVERSITY · PI KENNA, GEORGE A. · 2007 to 2010
$1.5M
Mifepristone As A Pharmacological Intervention For Stress-Induced Alcohol DrinkingK01AA023867 · NIAAA · BROWN UNIVERSITY · PI HAASS-KOFFLER, CAROLINA LUISA · 2016 to 2020
$901k
Effects of Ghrelin on Alcohol Cue Reactivity and CravingR21AA019709 · NIAAA · BROWN UNIVERSITY · PI KENNA, GEORGE A. · 2010 to 2011
$436k
A Novel Pharmacotherapy for Alcoholism and Alcohol Liver DiseaseR21AA021128 · NIAAA · BROWN UNIVERSITY · PI KENNA, GEORGE A. · 2012 to 2013
$431k
Doxazosin an a1 Antagonist for Alcohol DependenceR21AA019994 · NIAAA · BROWN UNIVERSITY · PI KENNA, GEORGE A. · 2011 to 2012
$425k
Effect of Baclofen on Alcohol Cue-Elicited Urges to Drink and SmokeR03AA020169 · NIAAA · BROWN UNIVERSITY · PI KENNA, GEORGE A. · 2010 to 2011
$79k
Intramural NIH HHSNIAAA NIH HHS 5T32AA007459-28NIAAA NIH HHS K01 AA023867NIAAA NIH HHS R01 AA015753NIAAA NIH HHS R01 AA016079NIAAA NIH HHS R01-AA016079NIAAA NIH HHS R03 AA020169NIAAA NIH HHS R03AA020169NIAAA NIH HHS R21 AA019709NIAAA NIH HHS R21AA019709NIAAA NIH HHS R21 AA019994NIAAA NIH HHS R21 AA021128NIAAA NIH HHS R21AA021128NIAAA NIH HHS T32 AA007459
6 · The paper itself

Abstract

Research on the concept of craving may lead to better understanding of the biobehavioural circuitries that contribute to the complexity of alcohol use disorders (AUDs). The experiences described as craving or desire to drink are often associated with physical responses such as increased salivation and heart rate, and alteration of stress hormones, as well as psychological responses such as anxiety and depression. Greater craving has been associated with an increased probability of alcohol relapse. Reversal of craving, which is understood as a symptom of protracted abstinence, offers the possibility of preventing relapses and treating alcoholism. Various medications have been studied to establish whether they are able to reduce craving; however, the results obtained from clinical studies have been inconsistent. Here, we review the interdisciplinary models developed to evaluate craving, then the different approaches used to assess and measure craving and, finally, the medications utilized and tested to lessen craving in patients suffering from AUDs.

Indexed as

CravingAlcohol-Related DisordersAnimalsBehavior, AddictiveExcitatory Amino Acid AntagonistsHumansReceptors, N-Methyl-D-AspartateSerotonin AntagonistsExcitatory Amino Acid AntagonistsReceptors, N-Methyl-D-AspartateSerotonin Antagonists

Identifiers

PMID24573997
PMCPMC3990000

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.